HSPB6 and myeloid sarcoma: Some HSPB6 immunolabelling was also observed in the parenchyma of non-neurological controls (Fig. 3a) but evaluation of the frequency of astrocytes displaying high expression of HSPB6 revealed no significant differences between control WM (7.5 ± 2.7 %) and NAWM in MS patients (6.7 ± 1.9 %) (Fig. 3a, b, i).